Cost-Effectiveness of Interferon-Free Therapy for Hepatitis C in Germany

Below:  Probabilistic sensitivity analysis. Probabilistic Sensitivity Analysis shows 3000 random draws for each of the four therapies. Out of the 3000 draws, SOF/SMV would be above or on the efficiency frontier in 10.0 % of the simulations, while SOF/RBV would never meet the requirement

The efficiency frontier is defined by dual therapy and first generation direct-acting antiviral Boceprevir, yielding a maximum of € 1,447.69 per additional percentage point of sustained virologic response gained. Even without rebates, Sofosbuvir/Simeprevir is very close with € 1,560.13 per additional percentage point. It is both more effective and less expensive than Sofosbuvir/Ribavirin.

In addition to higher sustained virologic response rates, new direct-acting antivirals save long-term costs by preventing complications such as liver cirrhosis, hepatocellular carcinoma and ultimately liver transplants, thereby offsetting part of higher drug costs. Our findings are in line with the guidance published by German Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends Sofosbuvir/Simeprevir for Interferon ineligible or intolerant patients.

Via:  http://ht.ly/Qj1Q5 HT @jlugiessen